{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 60,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a split-layout to contrast clinical data findings with the strategic clinical development plan.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/40",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Potential to be First Precision Medicine in DLBCL to Target a Genetically-defined Population (MYD88MT)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25f8be30-52a1-4ca2-a4e4-9a6c5c5353f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "list",
      "text": "PK and PD profiles in DL1-4* consistent with preclinical data supporting once every three-week dosing regimen. KT-413 achieved dose-dependent degradation of up to 70% IRAK4 and 96-100% Ikaros and Aiolos in PBMC after a single dose.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "853dc6d9-60d5-4bf5-b336-c8ed56aa18f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.52,
        "y": 0.39
      },
      "kind": "list",
      "text": "Profound antitumor activity in preclinical models both in single agent and combination. Clinical strategy in place to enable accelerated approval.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7302cc5-156d-4e92-b35f-699840b8b084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.04,
        "y": 0.64
      },
      "kind": "list",
      "text": "The most common adverse events were fatigue, cough and pyrexia.** No DLTs or drug-related neutropenia were observed in the study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1ad37d0-0666-4b1d-a345-ed27cd945fe2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "As of the data cut-off of June 1, 2023:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2191d9a-dfd9-4c19-b25c-2ede1edc8196",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*DL1-3 have been completed and DL4 remains open to accrual. **AEs related to KT-413 were all Grade 1 and 2; SAEs (Gr. 4 sepsis and Gr. 4 lung infection) reported in one patient in DL3 occurred outside of the DLT window.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a60dfc8-1523-4b48-9f04-e4f7e47dcf4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.72,
        "x": 0.14,
        "y": 0.04
      },
      "kind": "title",
      "text": "Desired Translation of PK, PD and Safety of KT-413",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "076df65e-d3ff-434b-853d-774a6be1cb9a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}